Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is a promising investment for several reasons. The company has entered a lucrative deal to monetize a portion of its Jemperli revenue, providing significant cash flow to fund pipeline development. Additionally, Anaptys is focused on growing its royalty revenue through its drug imsidolimab, which has shown potential for treating multiple inflammatory conditions and has promising results in Phase 3 trials for colon cancer and GPP. Despite a legal dispute with GSK/Tesaro, Anaptys is still expected to be a strong investment with its growth prospects and potential for significant royalties.

Bears say

AnaptysBio is an innovative biotechnology company with promising antibody product candidates in clinical development for unmet medical needs, specifically in the areas of inflammation and immuno-oncology. Their collaboration with Tesaro provides potential for milestone payments and royalties, and their financial backing from Sagard Holdings and Celgene provides stability. The recent court ruling in their favor and potential for upsides in royalty rates further solidifies AnaptysBio's outlook.

AnaptysBio (ANAB) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 10 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.